An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease

Conditions:   Non-Small Cell Lung Cancer;   Non-Small-Cell Lung Carcinoma;   Circulating Tumor DNA Interventions:   Biological: Nivolumab;   Drug: Vinorelbine;   Drug: Gemcitabine;   Drug: Docetaxel;   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Paclitaxel;   Other: Observation Sponsor:   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials